Clinical observation of intravitreal injection of Conbercept treating exudative age-related macular degeneration_Chinese Journal of Ocular Fundus Diseases

Authors：

YuLan ,  ChenChangzheng , YizuoHuizi , 苏钰 , 周芸芸 , 郑红梅 , 戚沆

Eye Center, People's Hospital of Wuhan University, Wuhan 430060, China;

Corresponding author：

ChenChangzheng, Email: whuchenchzh@163.com

Keywords：

Choroidal neovascularization/drug therapy; Wet macular degeneration/drug therapy; Angiogenesis inhibitors/therapeutic use; Antibodies, monoclonal/therapeutic use

DOI：

10.3760/cma.j.issn.1005-1015.2015.03.011

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To observe the clinical efficiency of intravitreal Conbercept on exudative age-related macular degeneration (eAMD). Methods This is an open and prospective study without control trial. Twenty eyes from 20 patients (19 males and 1 female) with eAMD diagnosed by fundus fluorescein angiography (FFA) and indocyanine green angiography (ICGA) were enrolled in this study. Before the injection, best-corrected visual acuity (BCVA) of early treatment of diabetic retinopathy study (ETDRS), non-contact tonometer, ophthalmoscope, fundus photography, fundus fluorescein angiograph (FFA), indocyanine green angiography (ICGA) and optical coherence tomography (OCT) were examined. The initial average letters of ETDRS acuity were 41.20±22.61, range from 8 to 80. The initial average central retina thickness (CRT) was (345.25±131.96) μm, range from 152 to 770 μm.All affected eyes were treated with intravitreal conbercept 0.05 ml (10 mg/ml). The patients were followed up for 6 to 9 months, with the mean time of (7.35±0.99) months.The BCVA, CRT after treatment were compared with baseline using paired t-test. Results During the 1, 3, 6, 12 months after treatment and the latest follow up, the mean BCVA were all improved with statistically significant difference (t=5.85, 7.09, 7.44, 7.25; P < 0.05). At 1 month ater treatment, the mean BCVA was obviously improved in 6 eyes (30%), improved in 8 eyes (40%), stable in 6 eyes (30%). At latest follow up, the mean BCVA was obviously improved in 6 eyes (30%), improved in 9 eyes (45%), stable in 5 eyes (25%). During the 1, 3, 6, 12 months after treatment and the latest follow up, the mean CRT were all decreased with statistically significant difference (t=3.34, 3.78, 3.47, 3.44; P < 0.05). At latest follow up, the leakage in macula lutea disappeared in 6 eyes (30%), decreased in 11 eyes (55%) and increased in 3 eyes (15%). No adverse events such as secondary retinal detachment or endoophthalmitis were found during the follow-up duration. Conclusion Intravitreal conbercept is a safe and effective approach for eAMD, may improve visual acuity, exudation and macular edema.

Citation： YuLan, ChenChangzheng, YizuoHuizi. Clinical observation of intravitreal injection of Conbercept treating exudative age-related macular degeneration. Chinese Journal of Ocular Fundus Diseases, 2015, 31(3): 256-259. doi: 10.3760/cma.j.issn.1005-1015.2015.03.011 Copy

1.	Rudnicka AR, Jarrar Z, Wormald R, et al. Age and gender variations in age-related macular degeneration prevalence in populations of European ancestry:a meta-analysis[J]. Ophthalmology, 2012, 119(3):571-580.
2.	American Academy of Ophthalmology Retina Panel.Preferred Practice Pattern? Guidelines:comprehensive adult medical eye evaluation[EB/OL].San Francisco:American Academy of Ophthalmology, 2010[20l0-09-11]. http://one.Aao.Org/CE/PracticeGuidellnes/PPP.Aspx?p=1, .
3.	Takashi U, Yasuo N, Takuhiro Y, et al. Systemic vascular safety of ranibizumab for age-related macular degeneration:systematic review and meta-analysis of randomized trials[J]. Ophthalmology, 2014, 121(11):2193-2203.
4.	Emerson MV, Lauer AK. Current and emerging therapies for the treatment of age-related macular degeneration[J]. Clin Ophthalmol, 2008, 2(2):377-388.
5.	Li X, Xu G, Wang Y, et al. Safety and efficacy of conbercept in neovascular age-related macular degeneration:results from a 12-month randomized phase 2 study:AURORA study[J]. Ophthalmology, 2014, 121(9):1740-1747.
6.	张军军, 张美霞.渗出性老年性黄斑变性治疗方法的新选择[J].中华实验眼科杂志, 2012, 30(11):961-964.
7.	Wang Q, Li T, Wu Z, et al. Novel VEGF decoy receptor fusion protein conbercept targeting multiple VEGF isoforms provide remarkable anti-angiogenesis effect in vivo[J/OL].PLoS One, 2013, 8(8):70544[2013-08-12]. http://dx.plos.org/10.1371/journal.pone.0070544.
8.	Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration[J]. N Engl J Med, 2006, 355:1419-1431.
9.	Brown DM, Michels M, Kaiser PK, et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration:two-year results of the ANCHOR Study[J]. Ophthalmology, 2009, 116(1):57-65.
10.	Singer MA, Awh CC, Sadda S, et al. HORIZON:an openlabel extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration[J]. Ophthalmology, 2012, 119(6):1175-1183.
11.	Rofagha S, Bhisitkul RB, Boyer DS, et al.Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON:a multicenter cohort study (SEVEN-UP)[J]. Ophthalmology, 2013, 120(11):2292-2299.
12.	Lalwani GA, Rosenfeld PJ, Fung AE, et al.A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration:year 2 of the PRONTO Study[J].Am J Ophthalmol, 2009, 148(1):43-58.
13.	Gicomelli G, Giansanti F, Finocchio L, et al. Results of intravitreal ranibizumab with a prn regimen in the treatment of extrafoveal and juxtafoveal neovascular membranes in age-related macular degeneration[J]. Retina, 2014, 34(5):860-867.
14.	Holz FG, Amoaku W, Donate J, et al.Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration:the SUSTAIN study[J]. Ophthalmology, 2011, 118(4):663-671.
15.	Brown DM, Kaiser PK, Michels M, et al.Ranibizumab versus verteporfin for neovascular age-related macular degeneration[J]. N Engl J Med, 2006, 355(14):1432-1444.
16.	Zhang M, Zhang JJ, Yan M, et al. Recombinant anti-vascular endothelial growth factor fusion protein efficiently suppresses choroidal neovascularization in monkeys[J]. Mol Vision, 2008, 14:37-49.
17.	Zhang M, Yu DC, Yang C, et al. The pharmacology study of a new recombinant human VEGF receptor-Fc fusion protein on experimental choroidal neovascularization[J]. Pharm Res, 2009, 26(1):204-210.
18.	Zhang M, Zhang JJ, Yan M, et al. KH902 Phase 1 Study Group. A phase 1 study of KH902, a vascular endothelial growth factor receptor decoy, for exudative age-related macular degeneration[J]. Ophthalmology, 2011, 118(4):672-678.
19.	Otsuji T, Nagai Y, Sho K, et al. Initial non-responders to ranibizumab in the treatment of age-related macular degegeration(AMD)[J]. Clin Ophthalmol, 2013, 7:1487-1490.
20.	张美霞.关于湿性年龄相关性黄斑变性抗血管内皮生长因子治疗中的无应答病例[J].中华眼科杂志, 2014, 50(6):406-410.

1. Rudnicka AR, Jarrar Z, Wormald R, et al. Age and gender variations in age-related macular degeneration prevalence in populations of European ancestry:a meta-analysis[J]. Ophthalmology, 2012, 119(3):571-580.
2. American Academy of Ophthalmology Retina Panel.Preferred Practice Pattern? Guidelines:comprehensive adult medical eye evaluation[EB/OL].San Francisco:American Academy of Ophthalmology, 2010[20l0-09-11]. http://one.Aao.Org/CE/PracticeGuidellnes/PPP.Aspx?p=1, .
3. Takashi U, Yasuo N, Takuhiro Y, et al. Systemic vascular safety of ranibizumab for age-related macular degeneration:systematic review and meta-analysis of randomized trials[J]. Ophthalmology, 2014, 121(11):2193-2203.
4. Emerson MV, Lauer AK. Current and emerging therapies for the treatment of age-related macular degeneration[J]. Clin Ophthalmol, 2008, 2(2):377-388.
5. Li X, Xu G, Wang Y, et al. Safety and efficacy of conbercept in neovascular age-related macular degeneration:results from a 12-month randomized phase 2 study:AURORA study[J]. Ophthalmology, 2014, 121(9):1740-1747.
6. 张军军, 张美霞.渗出性老年性黄斑变性治疗方法的新选择[J].中华实验眼科杂志, 2012, 30(11):961-964.
7. Wang Q, Li T, Wu Z, et al. Novel VEGF decoy receptor fusion protein conbercept targeting multiple VEGF isoforms provide remarkable anti-angiogenesis effect in vivo[J/OL].PLoS One, 2013, 8(8):70544[2013-08-12]. http://dx.plos.org/10.1371/journal.pone.0070544.
8. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration[J]. N Engl J Med, 2006, 355:1419-1431.
9. Brown DM, Michels M, Kaiser PK, et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration:two-year results of the ANCHOR Study[J]. Ophthalmology, 2009, 116(1):57-65.
10. Singer MA, Awh CC, Sadda S, et al. HORIZON:an openlabel extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration[J]. Ophthalmology, 2012, 119(6):1175-1183.
11. Rofagha S, Bhisitkul RB, Boyer DS, et al.Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON:a multicenter cohort study (SEVEN-UP)[J]. Ophthalmology, 2013, 120(11):2292-2299.
12. Lalwani GA, Rosenfeld PJ, Fung AE, et al.A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration:year 2 of the PRONTO Study[J].Am J Ophthalmol, 2009, 148(1):43-58.
13. Gicomelli G, Giansanti F, Finocchio L, et al. Results of intravitreal ranibizumab with a prn regimen in the treatment of extrafoveal and juxtafoveal neovascular membranes in age-related macular degeneration[J]. Retina, 2014, 34(5):860-867.
14. Holz FG, Amoaku W, Donate J, et al.Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration:the SUSTAIN study[J]. Ophthalmology, 2011, 118(4):663-671.
15. Brown DM, Kaiser PK, Michels M, et al.Ranibizumab versus verteporfin for neovascular age-related macular degeneration[J]. N Engl J Med, 2006, 355(14):1432-1444.
16. Zhang M, Zhang JJ, Yan M, et al. Recombinant anti-vascular endothelial growth factor fusion protein efficiently suppresses choroidal neovascularization in monkeys[J]. Mol Vision, 2008, 14:37-49.
17. Zhang M, Yu DC, Yang C, et al. The pharmacology study of a new recombinant human VEGF receptor-Fc fusion protein on experimental choroidal neovascularization[J]. Pharm Res, 2009, 26(1):204-210.
18. Zhang M, Zhang JJ, Yan M, et al. KH902 Phase 1 Study Group. A phase 1 study of KH902, a vascular endothelial growth factor receptor decoy, for exudative age-related macular degeneration[J]. Ophthalmology, 2011, 118(4):672-678.
19. Otsuji T, Nagai Y, Sho K, et al. Initial non-responders to ranibizumab in the treatment of age-related macular degegeration(AMD)[J]. Clin Ophthalmol, 2013, 7:1487-1490.
20. 张美霞.关于湿性年龄相关性黄斑变性抗血管内皮生长因子治疗中的无应答病例[J].中华眼科杂志, 2014, 50(6):406-410.

Chinese Journal of Ocular Fundus Diseases

Clinical observation of intravitreal injection of Conbercept treating exudative age-related macular degeneration

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content